Nonalcoholic fatty liver disease: opinions, population served, and management from a sample of French hepato(gastroentero)logists (PERSEPT study).
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
31
3
2022
medline:
7
6
2022
entrez:
30
3
2022
Statut:
ppublish
Résumé
The three-fold objective of this study was to describe the opinions, the population served, and tools used for the management of nonalcoholic fatty liver disease (NAFLD) by French hepato(gastro)enterologists (HGEs). Seventy-five French HGEs working in hospitals or in private practice, who regularly managed patients with NAFLD, completed three questionnaires: one about their opinions about disease management, one on the 10 first patients with NAFLD they saw in February 2020, and the third about the first five patients meeting the 2016 European Association for the Study of the Liver criteria for specialist referral. Management of NAFLD was seen as challenging, complex, time-consuming, and frustrating. Available treatments were considered to be unsatisfactory by most participants. In the whole population studied (671 patients), 41% were obese, 50% overweight, 49% had type 2 diabetes, 61% dyslipidemia, 51% arterial hypertension, 57% nonalcoholic steato-hepatitis (NASH), 37% advanced fibrosis, and 19% cirrhosis. In the subgroup of 313 patients needing specialist referral, the use of liver biopsy was low (30%) and decreasing, whereas vibration-controlled transient elastometry was high (66%) and increasing; blood fibrosis tests were rarely used. NASH was usually diagnosed without liver biopsy. Nutritional counseling was provided to 3/4 patients, physical activity counseling in 1/5. A personalized therapeutic project was defined in less than one-third of patients. Ursodeoxycholic acid and vitamin E were used in a minority of patients. The management of NAFLD is not considered satisfactory by French HGE who care for a relatively severe population. Noninvasive assessment of fibrosis and multidisciplinary management should be improved.
Identifiants
pubmed: 35352691
doi: 10.1097/MEG.0000000000002369
pii: 00042737-202207000-00010
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
791-800Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Nabi O, Lacombe K, Boursier J, Mathurin P, Zins M, Serfaty L. Prevalence and risk factors of nonalcoholic fatty liver disease and advanced fibrosis in general population: the French Nationwide NASH-CO Study. Gastroenterology. 2020; 159:791–793.e2.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64:1388-1402.
Serfaty L. Management of patients with non-alcoholic steatohepatitis (NASH) in real life. Liver Int. 2018; 38 Suppl 1:52–55.
Hofmann WP, Buggish P, Schubert L, Dikopoulos N, Schwenzer J, Muche M, et al. The fatty liver assessment in Germany (FLAG) cohort study identifies large heterogeneity in health care. J Hep Reports. 2020; 2:100168.
Ratziu V, Cadranel JF, Serfaty L, Denis J, Renou C, Delassalle P, et al. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol. 2012; 57:376–383.
Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, et al. Patient determinants for histologic diagnosis of NAFLD in the real world: A TARGET-NASH study. Hepatol Commun. 2021; 5:938–946.
SNFGE. Etat des lieux de l’hépatogastroentérologie en France. 2020. https://www.cnp-hge.fr/wp-content/uploads/2020/09/etat-des-lieux-de-l-hepato-gastroenterologie-en-france-rapport-synthetique-1.pdf . [Accessed 3 March 2022].
Friguet JL. La retraite des spécialistes: quand? combien? quelle solvabilité? 2020. https://www.syndicatavenirspe.fr/wp-content/uploads/2020/02/AvenirSpe_Friguet20200215.pdf . [Accessed 3 March 2022]
Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009; 51:371–379.
Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, et al.; Liver Forum Case Definitions Working Group. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum. Hepatology. 2019; 70:1841–1855.
Boursier J, Tsochatzis EA. Case-finding strategies in non-alcoholic fatty liver disease. JHEP Rep. 2021; 3:100219.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67:328–357.
Boursier J, Guillaume M, Bouzbib C, Lannes A, Pais R, Smatti S, et al. Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2022; 46:101769.
Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, et al. Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: expert panel recommendations. Am J Gastroenterol. 2021; 116:254–262.
Crossan C, Majumdar A, Srivastava A, Thorburn D, Rosenberg W, Pinzani M, et al. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: diagnostic accuracy and cost analysis. Liver Int. 2019; 39:2052–2060.
Ratziu V. Treatment of NASH with ursodeoxycholic acid: pro. Clin Res Hepatol Gastroenterol. 2012; 36 Suppl 1:S41–S45.
Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, et al. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Ann Hepatol. 2020; 19:674–690.
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41:2669–2701.
Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43:487–493.